[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569513":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":59,"collaborators":24,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":24,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":24,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Alberta","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants living with T2D","EXPERIMENTAL","Randomly assigned to consume either traditional kefir or milk as a placebo.",[13,14],"Dietary Supplement: Traditional Kefir","Dietary Supplement: Milk (placebo)",{"label":16,"type":10,"description":11,"interventionNames":17},"Participants with higher risk of T2D",[13,14],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT","Traditional Kefir","350 mL\u002Fday of traditional fermented\u002Fprepared kefir",[9,16],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Milk (placebo)","350 mL\u002Fday of commercial 2% fat milk",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Paulina Aldana Hernandez, PhD","CONTACT","780-492-9506","paldana@ualberta.ca",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Edmonton","Alberta","T6G 2E1","Canada","CA",{"type":44,"coordinates":45},"Point",[46,47],-113.46871,53.55014,{"lat":47,"lon":46},[50,51,54,57],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},{"name":52,"role":53,"phone":24,"phoneExt":24,"email":24},"Benjamin Willing, PhD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":56,"phone":24,"phoneExt":24,"email":24},"Caroline Richard, PhD","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":24,"phoneExt":24,"email":24},"Laurie Mereu, Dr",{"type":60,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100569513","improving-health-outcomes-with-kefir-100569513",false,"NCT06695221","Improving Health Outcomes With Kefir","Inclusion Criteria:\n\n1. females and males (24-70 years old) living in Edmonton (or Edmonton area\u002Fdriving distance);\n2. overweight or obesity (BMI \\>25 Caucasian, \\>23 Asian);\n3. at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol\u002FL or\u002Fand HbA1C ≥ 5.5 - 6.4%); or\n4. with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol\u002FL or\u002Fand HbA1C ≥ 6.5%).\n\nExclusion Criteria:\n\n1. a usual high intake (maximum intake 3 servings\u002Fweek) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months;\n2. gastrointestinal (GI) disorders of any kind;\n3. being pregnant or breastfeeding;\n4. monogenic dyslipidemias and endocrine disorders except for diabetes;\n5. use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents);\n6. any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.);\n7. having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test.\"","ALL","24 Years","70 Years",{"count":71,"type":72},156,"ESTIMATED","INTERVENTIONAL",[75],"NA","The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.",[78,79,80],"Systemic Inflammatory Response","Diabetes Mellitus, Type 2","Cardiovascular Diseases",[82,83,84,85,86],"Kefir","Systemic inflammation","Vascular markers","Gut microbiota","Fermented Foods","2026-05-06",{"date":89,"type":90},"2026-05-08","ACTUAL",{"date":92,"type":90},"2026-03-24",{"date":94,"type":72},"2027-12",{"name":5,"class":6},1]